Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IBUPROFEN ANDAs BASED ON DATA GENERATED PRIOR TO ANDA/PATENT LAW

Executive Summary

IBUPROFEN ANDAs BASED ON DATA GENERATED PRIOR TO ANDA/PATENT LAW should not be approved, Boots counsel James Johnstone (Wiley and Rein) maintained in a May 13 petition to FDA. The firm petitioned FDA to "refrain from approving . . . ANDAs under 505(j) or paper NDAs under 505(b)(2) which rely on data generated as a result of the patent infringing use or manufacture of ibuprofen or ibuprofen containing products prior to the Sept. 24, 1984 effective date of the Drug Price Competition and Patent Term Restoration Act." Boots' petition notes that the firm is currently engaged in litigation over Mylan's alleged pre-September testing of ibuprofen for its pending ibuprofen ANDA. The petition requests that FDA not approve any ibuprofen generic applications until the Boots/Mylan litigation resolves the legal issue of whether pre-ANDA/patent law testing constitutes patent infringement under Roche v. Bolar. Johnstone stated the Boots' position is: "(1) that pre-Sept. 24, 1984 unauthorized manufacture and testing of ibuprofen was and is infringement, (2) that the 1984 act did not and could not retroactively change the law applicable to such pre-enactment infringement, and (3) that the patent holder is entitled to relief to prevent the infringer from benefiting from such infringement to the patent holder's detriment." Referring to the lawsuit, Johnstone stated that if Boots' "position is upheld, it would be wrong and wasteful for FDA to approve ANDAs or paper NDAs relying on data generated through patent infringement." The petition asserts that while patent holders could seek judicial "relief against the new NDA holders (and possibly FDA), such litigation would be wasteful and likely to adversely affect the public interest by creating more delay in generic drugs reaching the market than a clear policy of refusing to consider data generated through infringement." If FDA "believes it should not withhold approval of infringing applications," the petition requests that the agency "(1) immediately amend 21 CFR 314(b) to provide for 30 days prior notice to the patentee if FDA has decided to approve an application for which it appears that data was developed in derogation of patent rights and (2) give petitioner such notice with respect to any ANDAs or paper NDAs for ibuprofen."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008376

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel